NCT00291720View on ClinicalTrials.gov

Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

PHASE2CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Chronic Kidney DiseaseCardiovascular Disease

Interventions

DRUG

Spironolactone

All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.

DRUG

Placebo

matching placebo

Trial Locations (1)

B15 2TH

University Hospital Birmingham, Birmingham

All Listed Sponsors

collaborator

British Heart Foundation

OTHER

lead

University Hospital Birmingham

OTHER

NCT00291720 - Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure? | Biotech Hunter | Biotech Hunter